New Insights into von Willebrand disease and platelet function

Seminars in Thrombosis and Hemostasis

Volumn 38, Issue 1, 2012, Pages 55-63

  Szántó, Tmea ^a   Joutsi Korhonen, Lotta ^a   Deckmyn, Hans ^b   Lassila, Riitta ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

high shear; platelet adhesion; von Willebrand disease; von Willebrand factor

Indexed keywords

BLOOD CLOTTING FACTOR 8; GLYCOPROTEIN IB ALPHA; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; GLYCOPROTEIN VI; THROMBIN; VON WILLEBRAND FACTOR;

CONFERENCE PAPER; HEMOSTASIS; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOSIS; VON WILLEBRAND DISEASE;

EID: 84857025846     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0031-1300952     Document Type: Conference Paper

References (76)

1. Ruggeri ZM. Platelets in atherothrombosis. Nat Med: 2002; 8 11 1227 1234 (Pubitemid 35373553)
2. Sixma JJ, van Zanten GH, Huizinga EG., et al. Platelet adhesion to collagen: an update. Thromb Haemost: 1997; 78 1 434 438 (Pubitemid 27289280)
3. Moroi M, Jung SM, Nomura S, Sekiguchi S, Ordinas A, Diaz-Ricart M. Analysis of the involvement of the von Willebrand factor-glycoprotein Ib interaction in platelet adhesion to a collagen-coated surface under flow conditions. Blood: 1997; 90 11 4413 4424 (Pubitemid 27508447)
4. Savage B, Almus-Jacobs F, Ruggeri ZM. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell: 1998; 94 5 657 666 (Pubitemid 28427584)
5. Christophe O, Obert B, Meyer D, Girma JP. The binding domain of von Willebrand factor to sulfatides is distinct from those interacting with glycoprotein Ib, heparin, and collagen and resides between amino acid residues Leu 512 and Lys 673. Blood: 1991; 78 9 2310 2317
6. Mazurier C, Ribba AS, Gaucher C, Meyer D. Molecular genetics of von Willebrand disease. Ann Genet: 1998; 41 1 34 43 (Pubitemid 28185043)
7. Emsley J, Cruz M, Handin R, Liddington R. Crystal structure of the von Willebrand Factor A1 domain and implications for the binding of platelet glycoprotein Ib. J Biol Chem: 1998; 273 17 10396 10401 (Pubitemid 28227648)
8. Bienkowska J, Cruz M, Atiemo A, Handin R, Liddington R. The von willebrand factor A3 domain does not contain a metal ion-dependent adhesion site motif. J Biol Chem: 1997; 272 40 25162 25167 (Pubitemid 27415701)
9. Lankhof H, van Hoeij M, Schiphorst ME., et al. A3 domain is essential for interaction of von Willebrand factor with collagen type III. Thromb Haemost: 1996; 75 6 950 958 (Pubitemid 26355353)
10. Siedlecki CA, Lestini BJ, Kottke-Marchant KK, Eppell SJ, Wilson DL, Marchant RE. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood: 1996; 88 8 2939 2950 (Pubitemid 26357374)
11. Novk L, Deckmyn H, Damjanovich S, Hrsfalvi J. Shear-dependent morphology of von Willebrand factor bound to immobilized collagen. Blood: 2002; 99 6 2070 2076 (Pubitemid 34525490)
12. Ulrichts H, Udvardy M, Lenting PJ., et al. Shielding of the A1 domain by the DD3 domains of von Willebrand factor modulates its interaction with platelet glycoprotein Ib-IX-V. J Biol Chem: 2006; 281 8 4699 4707 (Pubitemid 43847729)
13. Doggett TA, Girdhar G, Lawsh A., et al. Selectin-like kinetics and biomechanics promote rapid platelet adhesion in flow: the GPIb(alpha)-vWF tether bond. Biophys J: 2002; 83 1 194 205 (Pubitemid 34694731)
14. Zhang X, Halvorsen K, Zhang CZ, Wong WP, Springer TA. Mechanoenzymatic cleavage of the ultralarge vascular protein von Willebrand factor. Science: 2009; 329 1330 1334
15. Tsai HM. Mechanisms of microvascular thrombosis in thrombotic thrombocytopenic purpura. Kidney Int Suppl: 2009; 112 112 S11 S14
16. Ruggeri ZM, Zimmerman TS. Variant von Willebrands disease: characterization of two subtypes by analysis of multimeric composition of factor VIII/von Willebrand factor in plasma and platelets. J Clin Invest: 1980; 65 6 1318 1325 (Pubitemid 10122373)
17. Miller JL, Kupinski JM, Castella A, Ruggeri ZM. von Willebrand factor binds to platelets and induces aggregation in platelet-type but not type IIB von Willebrand disease. J Clin Invest: 1983; 72 5 1532 1542 (Pubitemid 14229032)
18. Casonato A, Gallinaro L, Cattini MG., et al. Reduced survival of type 2B von Willebrand factor, irrespective of large multimer representation or thrombocytopenia. Haematologica: 2010; 95 8 1366 1372
19. Dong JF, Berndt MC, Schade A, McIntire LV, Andrews RK, Lpez JA. Ristocetin-dependent, but not botrocetin-dependent, binding of von Willebrand factor to the platelet glycoprotein Ib-IX-V complex correlates with shear-dependent interactions. Blood: 2001; 97 1 162 168 (Pubitemid 32061256)
20. Kasirer-Friede A, Cozzi MR, Mazzucato M, De Marco L, Ruggeri ZM, Shattil SJ. Signaling through GP Ib-IX-V activates alpha IIb beta 3 independently of other receptors. Blood: 2004; 103 9 3403 3411 (Pubitemid 38525671)
21. Resndiz JC, Kroll MH, Lassila R. Protease-activated receptor-induced Akt activationregulation and possible function. J Thromb Haemost: 2007; 5 12 2484 2493 (Pubitemid 350154360)
22. Reininger AJ, Heijnen HF, Schumann H, Specht HM, Schramm W, Ruggeri ZM. Mechanism of platelet adhesion to von Willebrand factor and microparticle formation under high shear stress. Blood: 2006; 107 9 3537 3545
23. Emsley J, Knight CG, Farndale RW, Barnes MJ, Liddington RC. Structural basis of collagen recognition by integrin alpha2beta1. Cell: 2000; 101 1 47 56
24. Siljander PR, Munnix IC, Smethurst PA., et al. Platelet receptor interplay regulates collagen-induced thrombus formation in flowing human blood. Blood: 2004; 103 4 1333 1341 (Pubitemid 38168645)
25. Schoolmeester A, Vanhoorelbeke K, Katsutani S., et al. Monoclonal antibody IAC-1 is specific for activated alpha2beta1 and binds to amino acids 199 to 201 of the integrin alpha2 I-domain. Blood: 2004; 104 2 390 396 (Pubitemid 38900019)
26. Van de Walle GR, Schoolmeester A, Iserbyt BF., et al. Activation of alphaIIbbeta3 is a sufficient but also an imperative prerequisite for activation of alpha2beta1 on platelets. Blood: 2007; 109 2 595 602 (Pubitemid 46105957)
27. Inoue O, Suzuki-Inoue K, Ozaki Y. Redundant mechanism of platelet adhesion to laminin and collagen under flow: involvement of von Willebrand factor and glycoprotein Ib-IX-V. J Biol Chem: 2008; 283 24 16279 16282
28. Kulkarni S, Dopheide SM, Yap CL., et al. A revised model of platelet aggregation. J Clin Invest: 2000; 105 6 783 791 (Pubitemid 30164117)
29. Jackson SP, Nesbitt WS, Kulkarni S. Signaling events underlying thrombus formation. J Thromb Haemost: 2003; 1 7 1602 1612
30. Ni H, Yuen PS, Papalia JM., et al. Plasma fibronectin promotes thrombus growth and stability in injured arterioles. Proc Natl Acad Sci U S A: 2003; 100 5 2415 2419 (Pubitemid 36297513)
31. Andr P, Prasad KS, Denis CV., et al. CD40L stabilizes arterial thrombi by a beta3 integrindependent mechanism. Nat Med: 2002; 8 3 247 252 (Pubitemid 34250102)
32. Cosemans JM, Schols SE, Stefanini L., et al. Key role of glycoprotein Ib/V/IX and von Willebrand factor in platelet activation-dependent fibrin formation at low shear flow. Blood: 2011; 117 2 651 660
33. Whincup PH, Danesh J, Walker M., et al. von Willebrand factor and coronary heart disease: prospective study and meta-analysis. Eur Heart J: 2002; 23 22 1764 1770 (Pubitemid 35334269)
34. Smith NL, Rice KM, Bovill EG., et al. Genetic variation associated with plasma von Willebrand factor levels and the risk of incident venous thrombosis. Blood: 2011; 117 22 6007 6011
35. Wu D, Vanhoorelbeke K, Cauwenberghs N., et al. Inhibition of the von Willebrand (VWF)-collagen interaction by an antihuman VWF monoclonal antibody results in abolition of in vivo arterial platelet thrombus formation in baboons. Blood: 2002; 99 10 3623 3628 (Pubitemid 34534531)
36. Szanto T, Vanhoorelbeke K, Toth G., et al. Identification of a VWF peptide antagonist that blocks platelet adhesion under high shear conditions by selectively inhibiting the VWF-collagen interaction. J Thromb Haemost: 2009; 7 10 1680 1687
37. Kleinschnitz C, De Meyer SF, Schwarz T., et al. Deficiency of von Willebrand factor protects mice from ischemic stroke. Blood: 2009; 113 15 3600 3603
38. Sadler JE, Budde U, Eikenboom JC., et al. Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost: 2006; 4 10 2103 2114 (Pubitemid 44403432)
39. van Schooten CJ, Shahbazi S, Groot E., et al. Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo. Blood: 2008; 112 5 1704 1712
40. Hoylaerts MF, Nuyts K, Peerlinck K, Deckmyn H, Vermylen J. Promotion of binding of von Willebrand factor to platelet glycoprotein Ib by dimers of ristocetin. Biochem J: 1995; 306 Pt 2 453 463
41. Flood VH, Gill JC, Morateck PA., et al. Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor. Blood: 2010; 116 2 280 286
42. Flood VH, Friedman KD, Gill JC., et al. Limitations of the ristocetin cofactor assay in measurement of von Willebrand factor function. J Thromb Haemost: 2009; 7 11 1832 1839
43. National Institutes of Health Staff. NIH-NHLBI. Clinical guidelines: the diagnosis, evaluation and management of von Willebrand disease. Available at http://www.nhlbi.nih.gov/guidelines/vwd/1-frontmatter.htm. 2007. U.S. Department of Health and Human Services
44. Favaloro EJ, Bonar R, Marsden K. Lower limit of assay sensitivity: an under-recognised and significant problem in von Willebrand disease identification and classification. Clin Lab Sci: 2008; 21 3 178 183
45. Hillarp A, Stadler M, Haderer C, Weinberger J, Kessler CM, Römisch J. Improved performance characteristics of the von Willebrand factor ristocetin cofactor activity assay using a novel automated assay protocol. J Thromb Haemost: 2010; 8 10 2216 2223
46. Vanhoorelbeke K, Cauwenberghs N, Vauterin S, Schlammadinger A, Mazurier C, Deckmyn H. A reliable and reproducible ELISA method to measure ristocetin cofactor activity of von Willebrand factor. Thromb Haemost: 2000; 83 1 107 113 (Pubitemid 30045485)
47. Flood VH, Gill JC, Morateck PA., et al. Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD. Blood: 2011; 117 6 e67 e74
48. Bonnefoy A, Romijn RA, Vandervoort PA, VAN Rompaey I, Vermylen J, Hoylaerts MF. von Willebrand factor A1 domain can adequately substitute for A3 domain in recruitment of flowing platelets to collagen. J Thromb Haemost: 2006; 4 10 2151 2161 (Pubitemid 44400289)
49. Flood VH, Lederman CA, Wren JS., et al. Absent collagen binding in a VWF A3 domain mutant: utility of the VWF:CB in diagnosis of VWD. J Thromb Haemost: 2010; 8 6 1431 1433
50. Favaloro EJ. Collagen binding assay for von Willebrand factor (VWF:CBA): detection of von Willebrands Disease (VWD), and discrimination of VWD subtypes, depends on collagen source. Thromb Haemost: 2000; 83 1 127 135 (Pubitemid 30045488)
51. Siljander P, Lassila R. Studies of adhesion-dependent platelet activation: distinct roles for different participating receptors can be dissociated by proteolysis of collagen. Arterioscler Thromb Vasc Biol: 1999; 19 12 3033 3043 (Pubitemid 30029834)
52. Lisman T, Raynal N, Groeneveld D., et al. A single high-affinity binding site for von Willebrand factor in collagen III, identified using synthetic triple-helical peptides. Blood: 2006; 108 12 3753 3756 (Pubitemid 44864555)
53. Sztukowska M, Gallinaro L, Cattini MG., et al. Von Willebrand factor propeptide makes it easy to identify the shorter Von Willebrand factor survival in patients with type 1 and type Vicenza von Willebrand disease. Br J Haematol: 2008; 143 1 107 114
54. Ruggeri ZM. Type IIB von Willebrand disease: a paradox explains how von Willebrand factor works. J Thromb Haemost: 2004; 2 1 2 6 (Pubitemid 40185610)
55. Rayes J, Hommais A, Legendre P., et al. Effect of von Willebrand disease type 2B and type 2M mutations on the susceptibility of von Willebrand factor to ADAMTS-13. J Thromb Haemost: 2007; 5 2 321 328 (Pubitemid 46139457)
56. Sznt T, Schlammadinger A, Salles I., et al. Type 2B von Willebrand disease in seven individuals from three different families: phenotypic and genotypic characterization. Thromb Haemost: 2007; 98 1 251 254 (Pubitemid 47074204)
57. Virchow RLK. Thrombose und Embolie. Gefässentzündung und septische Infektion. Gesammelte Abhandlungen zur wissenschaftlichen Medicin 1856. Frankfurt am Main: Von Meidinger & Sohn; 219 732
58. Zabaneh D, Gaunt TR, Kumari M., et al. Genetic variants associated with Von Willebrand factor levels in healthy men and women identified using the HumanCVD BeadChip. Ann Hum Genet: 2011; 75 4 456 467
59. Smith NL, Chen MH, Dehghan A., et al. Wellcome Trust Case Control Consortium. Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium. Circulation: 2010; 121 12 1382 1392
60. Sznt T, Schlammadinger A, Staelens S., et al. The A/T1381 polymorphism in the A1-domain of von Willebrand factor influences the affinity of von Willebrand factor for platelet glycoprotein Ibalpha. Thromb Haemost: 2007; 98 1 178 185 (Pubitemid 47074194)
61. James PD, Paterson AD, Notley C., et al. Association of Hemophilia Clinic Directors of Canada. Genetic linkage and association analysis in type 1 von Willebrand disease: results from the Canadian type 1 VWD study. J Thromb Haemost: 2006; 4 4 783 792
62. Davies JA, Collins PW, Hathaway LS, Bowen DJ. Effect of von Willebrand factor Y/C1584 on in vivo protein level and function and interaction with ABO blood group. Blood: 2007; 109 7 2840 2846 (Pubitemid 46482079)
63. Mohlke KL, Purkayastha AA, Westrick RJ., et al. Mvwf, a dominant modifier of murine von Willebrand factor, results from altered lineage-specific expression of a glycosyltransferase. Cell: 1999; 96 1 111 120 (Pubitemid 29044158)
64. Favaloro EJ, Soltani S, McDonald J, Grezchnik E, Easton L, Favaloro JW. Reassessment of ABO blood group, sex, and age on laboratory parameters used to diagnose von Willebrand disorder: potential influence on the diagnosis vs the potential association with risk of thrombosis. Am J Clin Pathol: 2005; 124 6 910 917 (Pubitemid 41740192)
65. Gallinaro L, Cattini MG, Sztukowska M., et al. A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood: 2008; 111 7 3540 3545
66. Kunicki TJ, Baronciani L, Canciani MT., et al. An association of candidate gene haplotypes and bleeding severity in von Willebrand disease type 2A, 2B, and 2M pedigrees. J Thromb Haemost: 2006; 4 1 137 147
67. Kunicki TJ, Federici AB, Salomon DR., et al. An association of candidate gene haplotypes and bleeding severity in von Willebrand disease (VWD) type 1 pedigrees. Blood: 2004; 104 8 2359 2367 (Pubitemid 39331834)
68. Bauduer F, Ducout L. Is the assessment of von Willebrand disease prevalence an achievable challenge? The example of the French Basque Country where blood group O and factor XI deficiency are highly prevalent. J Thromb Haemost: 2004; 2 10 1724 1726 (Pubitemid 40192712)
69. Santos KF, Battisti V, Corra MdeC., et al. Enzymes that hydrolyze adenine nucleotides in platelets and polymorphisms in the alpha2 gene of integrin alpha2beta1 in patients with von Willebrand disease. Mol Cell Biochem: 2010; 340 1-2 249 256
70. Rugeri L, Beguin S, Hemker C., et al. Thrombin-generating capacity in patients with von Willebrands disease. Haematologica: 2007; 92 12 1639 1646 (Pubitemid 350248243)
71. Bguin S, Kumar R, Keularts I, Seligsohn U, Coller BS, Hemker HC. Fibrin-dependent platelet procoagulant activity requires GPIb receptors and von Willebrand factor. Blood: 1999; 93 2 564 570 (Pubitemid 29035737)
72. Forestier M, Resndiz JC, Pontiggia L, Lassila R, Beer JH. Platelet microparticle suppressing antibody against GP Ibalpha acts independently of the filamin cleavage and increases protein tyrosine phosphorylation. Blood Coagul Fibrinolysis: 2008; 19 8 801 806
73. Magwenzi SG, Ajjan RA, Standeven KF, Parapia LA, Naseem KM. Factor XIII supports platelet activation and enhances thrombus formation by matrix proteins under flow conditions. J Thromb Haemost: 2011; 9 4 820 833
74. Jurk K, Clemetson KJ, de Groot PG., et al. Thrombospondin-1 mediates platelet adhesion at high shear via glycoprotein Ib (GPIb): an alternative/backup mechanism to von Willebrand factor. FASEB J: 2003; 17 11 1490 1492
75. Rayes J, Hollestelle MJ, Legendre P., et al. Mutation and ADAMTS13-dependent modulation of disease severity in a mouse model for von Willebrand disease type 2B. Blood: 2010; 115 23 4870 4877
76. Pruss CM, Golder M, Bryant A., et al. Pathologic mechanisms of type 1 VWD mutations R1205H and Y1584C through in vitro and in vivo mouse models. Blood: 2011; 117 16 4358 4366